How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

Authors: Bonnetain, F. ^*, Borg, C., Adams, R.R., Ajani, J.A., Benson, A., Bleiberg, H., Chibaudel, B., Diaz-Rubio, E., Douillard, J.Y., Fuchs, C.S., Giantonio, B.J., Goldberg, R., Heinemann, V., Koopman, M., Labianca, R., Larsen, A.K., Maughan, T., Mitchell, E., Peeters, M., Punt, C.J.A., Schmoll, H.J., Tournigand, C., de Gramont, A.

Source: In Annals of Oncology September 2017 28(9):2077-2085

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Authors: Bleiberg, H. ^*, Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J.Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A.K., Mitchell, E., Schmoll, H.J., Sprumont, D., Zalcberg, J.

Source: In Annals of Oncology May 2017 28(5):922-930

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Authors: Modest, D.P. ^*, Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L.F., Giessen-Jung, C., Stahler, A., Schmoll, H.J., Jung, A., Kirchner, T., Tannapfel, A., Reinacher-Schick, A.

Source: In Annals of Oncology September 2016 27(9):1746-1753

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Authors: Van Cutsem, E. ^*, Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.

Source: In Annals of Oncology August 2016 27(8):1386-1422

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)

Authors: Grünwald, V. ^*, Keilholz, U., Boehm, A., Guntinas-Lichius, O., Hennemann, B., Schmoll, H.J., Ivanyi, P., Abbas, M., Lehmann, U., Koch, A., Karch, A., Zörner, A., Gauler, T.C.

Source: In Annals of Oncology March 2015 26(3):561-567

Quality assurance in the treatment of colorectal cancer: the EURECCA initiative

Authors: Breugom, A.J., Boelens, P.G., van den Broek, C.B.M., Cervantes, A., Van Cutsem, E., Schmoll, H.J., Valentini, V., van de Velde, C.J.H. ^*

Source: In Annals of Oncology August 2014 25(8):1485-1492

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Authors: Schmiegel, W. ^*, Reinacher-Schick, A. ^*, Arnold, D. ^*, Kubicka, S., Freier, W., Dietrich, G., Geißler, M., Hegewisch-Becker, S., Tannapfel, A., Pohl, M., Hinke, A., Schmoll, H.J., Graeven, U.

Source: In Annals of Oncology June 2013 24(6):1580-1587

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

Authors: Ruff, P., Ferry, D.R., Lakom, R., Prausova, J., Van Hazel, G.A., Hoff, P.M., Cunningham, D., Arnold, D., Schmoll, H.J.

Source: EUROPEAN JOURNAL OF CANCER -A-. 51(1):18-26

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN364290182&indx=1&recIds=ETOCRN364290182

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Authors: Schmoll, H.J. ^*, Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C.J., Balmana, J., Regula, J., Nagtegaal, I.D., Beets-Tan, R.G., Arnold, D., Ciardiello, F., Hoff, P., Kerr, D., Köhne, C.H., Labianca, R., Price, T., Scheithauer, W., Sobrero, A., Tabernero, J., Aderka, D., Barroso, S., Bodoky, G., Douillard, J.Y., El Ghazaly, H., Gallardo, J., Garin, A., Glynne-Jones, R., Jordan, K., Meshcheryakov, A., Papamichail, D., Pfeiffer, P., Souglakos, I., Turhal, S., Cervantes, A.

Source: In Annals of Oncology October 2012 23(10):2479-2516

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries

Authors: Saini, K.S., Taylor, C., Ramirez, A.-J., Palmieri, C., Gunnarsson, U., Schmoll, H.J., Dolci, S.M., Ghenne, C., Metzger-Filho, O., Skrzypski, M., Paesmans, M., Ameye, L., Piccart-Gebhart, M.J., de Azambuja, E. ^*

Source: In Annals of Oncology April 2012 23(4):853-859

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Authors: Daugaard, G. ^*, Skoneczna, I., Aass, N., De Wit, R., De Santis, M., Dumez, H., Marreaud, S., Collette, L., Lluch, J.R.G., Bokemeyer, C., Schmoll, H.J.

Source: In Annals of Oncology May 2011 22(5):1054-1061

Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types

Authors: Aapro, M.S., Schmoll, H.J., Jahn, F., Carides, A.D., Webb, R.T.

Source: CANCER TREATMENT REVIEWS. 39(1):113-117

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN327412319&indx=1&recIds=ETOCRN327412319

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Authors: Van Cutsem, E. ^*, Dicato, M., Arber, N., Berlin, J., Cervantes, A., Ciardiello, F., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Geva, R., Glimelius, B., Jones, R. Glynne, Grothey, A., Gruenberger, T., Haller, D., Haustermans, K., Labianca, R., Lenz, H.J., Minsky, B., Nordlinger, B., Ohtsu, A., Pavlidis, N., Rougier, P., Schmiegel, W., Van de Velde, C., Schmoll, H.J., Sobrero, A., Tabernero, J.

Source: In Annals of Oncology June 2010 21 Supplement 6:vi1-vi10

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study

Authors: Fizazi, K. ^*, Oldenburg, J., Dunant, A., Chen, I., Salvioni, R., Hartmann, J.T., De Santis, M., Daugaard, G., Flechon, A., de Giorgi, U., Tjulandin, S., Schmoll, H.J., Bouzy, J., Fossa, S.D., Fromont, G.

Source: In Annals of Oncology February 2008 19(2):259-264

Rectal cancer and synchronous metastases: Resection of primary tumor or not?

Authors: Trarbach, T., Schmoll, H.J.

Source: GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE. 33(12):1098-1100

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN263740808&indx=1&recIds=ETOCRN263740808

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

Authors: Schmoll, H.J. ^*, Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S.D., Skakkebaek, N.E., de Wit, R., Fizazi, K., Droz, J.P., Pizzocaro, G., Daugaard, G., de Mulder, P.H.M., Horwich, A., Oliver, T., Huddart, R., Rosti, G., Paz Ares, L., Pont, O., Hartmann, J.T., Aass, N., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Classen, J., Clemm, S., Culine, S., de Wit, M., Derigs, H.G., Dieckmann, K.P., Flasshove, M., Garcia del Muro, X., Gerl, A., Germa-Lluch, J.R., Hartmann, M., Heidenreich, A., Hoeltl, W., Joffe, J., Jones, W., Kaiser, G., Klepp, O., Kliesch, S., Kisbenedek, L., Koehrmann, K.U., Kuczyk, M., Laguna, M.P., Leiva, O., Loy, V., Mason, M.D., Mead, G.M., Mueller, R.P., Nicolai, N., Oosterhof, G.O.N., Pottek, T., Rick, O., Schmidberger, H., Sedlmayer, F., Siegert, W., Studer, U., Tjulandin, S., von der Maase, H., Walz, P., Weinknecht, S., Weissbach, L., Winter, E., Wittekind, C.

Source: In Annals of Oncology September 2004 15(9):1377-1399

Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)

Authors: Van Cutsem, E, Dicato, M, Wils, J, Cunningham, D, Diaz-Rubio, E, Glimelius, B, Haller, D, Johnston, P, Kerr, D, Koehne, C.H, Labianca, R, Minsky, B, Nordlinger, B, Roth, A, Rougier, P, Schmoll, H.J

Source: In European Journal of Cancer 2002 38(11):1429-1436

Localised disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management

Authors: Rades, D. ^*, Kühnel, G., Wildfang, I., Börner, A.R., Schmoll, H.J., Knapp, W.

Source: In Annals of Oncology November 2001 12(11):1605-1609

2089 Response to chemotherapy allows to identify mCRC patients most likely to benefit from maintenance immunotherapy: A post-hoc analysis from the IMPACT study

Authors: Scheithauer, W., Riera-Knorrenschild, J., Kopp, H.G., Mayer, F., Kroening, H., Nitsche, D., Kuhlmann, J., Ziebermayr, R., Andel, J., Arnold, D., Zurlo, A., Wittig, B., Schmoll, H.J.

Source: European journal of cancer. 51:S357-S358

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100031124255.0x000001&indx=1&recIds=ETOCvdc_100031124255.0x000001

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

Authors: Verslype, C., Van Cutsem, E. ^*, Dicato, M., Arber, N., Berlin, J.D. ⁴, Büchler, M.W., Cervantes, A., Ciardiello, F. ⁷, Ducreux, M., Douillard, J.Y., Grothey, A., Haller, D., Haustermans, K., Heinemann, V., Hidalgo, M., Labianca, R., Li, J., Marshall, J.L., Nordlinger, B., O'Reilly, E.M., Roth, A., Rougier, P., Ryan, D., Schmiegel, W., Seufferlein, T., Schmoll, H.J., Sobrero, A., Tabernero, J., Tempero, M., Van Laethem, J.L., Ychou, M., Zalcberg, J.

Source: In Annals of Oncology June 2013 24 Supplement 4:iv5-iv10